187 related articles for article (PubMed ID: 35678423)
1. Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.
Araki T; Wang J; Lawrence R; Kawakami Y
Endocrinology; 2022 Aug; 163(8):. PubMed ID: 35678423
[TBL] [Abstract][Full Text] [Related]
2. E2F1-mediated human POMC expression in ectopic Cushing's syndrome.
Araki T; Liu NA; Tone Y; Cuevas-Ramos D; Heltsley R; Tone M; Melmed S
Endocr Relat Cancer; 2016 Nov; 23(11):857-870. PubMed ID: 27935805
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
5. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
6. Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
Gentilin E; Tagliati F; Terzolo M; Zoli M; Lapparelli M; Minoia M; Ambrosio MR; Degli Uberti EC; Zatelli MC
J Endocrinol; 2013 Sep; 218(3):275-85. PubMed ID: 23814013
[TBL] [Abstract][Full Text] [Related]
7. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
[TBL] [Abstract][Full Text] [Related]
8. Why don't corticotroph tumors always produce Cushing's disease?
García-Martínez A; Cano DA; Flores-Martínez A; Gil J; Puig-Domingo M; Webb SM; Soto-Moreno A; Picó A
Eur J Endocrinol; 2019 Sep; 181(3):351-361. PubMed ID: 31319379
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation.
Kageyama K; Asari Y; Sugimoto Y; Niioka K; Daimon M
Endocr J; 2020 Feb; 67(2):177-184. PubMed ID: 31666445
[TBL] [Abstract][Full Text] [Related]
10. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
12. Effects of tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells.
Hagiwara R; Kageyama K; Iwasaki Y; Niioka K; Daimon M
Endocr J; 2022 Sep; 69(9):1053-1060. PubMed ID: 35296577
[TBL] [Abstract][Full Text] [Related]
13. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
14. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
15. Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas.
Pecori Giraldi F; Cassarino MF; Sesta A; Lasio G; Losa M
Neuroendocrinology; 2023; 113(6):606-614. PubMed ID: 36791678
[TBL] [Abstract][Full Text] [Related]
16. PPAR-gamma in Cushing's disease.
Heaney AP
Pituitary; 2004; 7(4):265-9. PubMed ID: 16416039
[TBL] [Abstract][Full Text] [Related]
17. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
18. Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease.
Granger N; de Fornel P; Devauchelle P; Segond S; Delisle F; Rosenberg D
J Vet Intern Med; 2005; 19(1):23-8. PubMed ID: 15715043
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.
Asari Y; Kageyama K; Sugiyama A; Kogawa H; Niioka K; Daimon M
Endocr J; 2019 Jun; 66(6):515-522. PubMed ID: 30880293
[TBL] [Abstract][Full Text] [Related]
20. Pro-opiomelanocortin gene expression in silent corticotroph-cell adenoma and Cushing's disease.
Nagaya T; Seo H; Kuwayama A; Sakurai T; Tsukamoto N; Nakane T; Sugita K; Matsui N
J Neurosurg; 1990 Feb; 72(2):262-7. PubMed ID: 2153197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
